Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. Lung Cancer: Non-Small Cell Lung Cancer Regimen: Ramucirumab + Docetaxel. Hematology-Oncology Therapy Updates, 26 July 2018. McGraw-Hill, 2018. AccessHemOnc. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428275§ionid=194479824APA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. (2018). Lung cancer: non-small cell lung cancer regimen: ramucirumab + docetaxel. Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. Hematology-oncology therapy updates. McGraw-Hill. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428275§ionid=194479824.MLA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. "Lung Cancer: Non-Small Cell Lung Cancer Regimen: Ramucirumab + Docetaxel." Hematology-Oncology Therapy Updates Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. McGraw-Hill, 2018, https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428275§ionid=194479824. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Lung Cancer: Non-Small Cell Lung Cancer Regimen: Ramucirumab + Docetaxel by Hematology-Oncology Therapy Listen + +Update to Chapter 22: Lung Cancer + Garon EB et al. Lancet. 2014;384:665-673 FDA and EMA prescribing information and miscellaneous sources Prophylaxis for infusion-related reaction from ramucirumab: Diphenhydramine 25–50 mg; administer intravenously, 30–60 minutes before starting ramucirumab, plus Acetaminophen 650–1000 mg; administer orally, 30–60 minutes before starting ramucirumab (only if history of grade 1/2 infusion reaction), plus Dexamethasone 8 mg; administer orally or intravenously, 30–60 minutes before starting ramucirumab (only if history of grade 1/2 infusion reaction; note dexamethasone is also indicated for prophylaxis with docetaxel, as described below) Ramucirumab 10 mg/kg; administer intravenously in 250 mL of 0.9% sodium chloride injection (0.9% NS) over 1 hour on day 1 before docetaxel, every 3 weeks (total dosage/cycle = 10 mg/kg) Prophylaxis for fluid retention and hypersensitivity reactions from docetaxel: Dexamethasone 8 mg/dose; administer orally twice daily for 3 days, starting the day before docetaxel is administered (total dose/cycle = 48 mg) Docetaxel 75 mg/m2; administer intravenously in a volume of 0.9% sodium chloride injection (0.9% NS) or 5% dextrose injection, USP, sufficient to produce a solution with concentration within the range of 0.3–0.74 mg/mL over 1 hour on day 1, every 3 weeks (total dosage/cycle = 75 mg/m2) Notes: Consider a starting docetaxel dose of 60 mg/m2 rather than 75 mg/m2 in East Asian patients based on findings of higher rates of neutropenia in this group in the REVEL study Some formulations of docetaxel contain alcohol; use caution or consider using a non-alcohol-containing formulation in patients who are sensitive to alcohol Supportive Care Antiemetic prophylaxis Emetogenic potential is LOW See Chapter 39 for antiemetic recommendations Hematopoietic growth factor (CSF) prophylaxis Primary prophylaxis MAY be indicated See Chapter 43 for more information Antimicrobial prophylaxis Risk of fever and neutropenia is MODERATE Antimicrobial primary prophylaxis to be CONSIDERED: Antibacterial—not indicated Antifungal—not indicated Antiviral—not indicated unless patient previously had an episode of HSV See Chapter 47 for more information + +Patient Population Studied + A multicenter, double-blind, randomized, phase 3 study of 1253 patients with pathologically confirmed, squamous or non-squamous, stage IV NSCLC who had progressed during or after a first-line platinum-based chemotherapy. Eligible patients were aged ≥18 years, with an Eastern Cooperative Oncology Group (ECOG) performance status score ≤1. Patients were not eligible if their only previous therapy for advanced or metastatic disease was EGFR tyrosine kinase inhibitor monotherapy. Patients received docetaxel with (1:1) ramucirumab or placebo + +Efficacy (N = 1253) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Median overall survival 10.5 months with docetaxel + ramucirumab 9.1 months with docetaxel + placebo HR 0.86, 95% CI 0.75–0.98, P = 0.023 Median progression-free survival 4.5 months with docetaxel + ramucirumab 3.0 months with docetaxel + placebo HR 0.76, 95% CI 0.68–0.86, P <0.0001 Objective response rate✫ 23% with docetaxel + ramucirumab 14% with docetaxel + placebo OR 1.89, 95% CI 1.41–2.54, P <0.0001 ✫Overall response rate is the percentage of patients who experienced a confirmed partial or complete response to the study drug + +Therapy Monitoring + Draw serum bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle Obtain CBC with differential at a minimum once per cycle, but initially also at days 10–14 Observe closely for hypersensitivity reactions, especially during the first and second ramucirumab infusions Monitor patients with preexisting effusions closely for possible exacerbation of effusions Monitor all patients for fluid retention. Median cumulative dose to onset of moderate/severe fluid retention was 819 mg/m2 of docetaxel Check blood pressure every 2 weeks or more frequently as indicated during treatment. Assess proteinuria by urine dipstick and/or urinary protein creatinine ratio at baseline and every 2 cycles. If protein ≥ 2+, then collect a 24-hour urine for protein measurement Assess thyroid function at outset and every 3 months while on therapy + +Treatment Modifications + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print RAMUCIRUMAB DOSE MODIFICATIONS Starting dose 10 mg/kg (starting ramucirumab dose for lung cancer) Dose level −1 8 mg/kg Dose level −2 6 mg/kg G1/2 infusion-related Stop ramucirumab. Administer dexamethasone intravenously at commonly used antiemetic doses of 8–20 mg (or equivalent) and acetaminophen, then resume infusion at 50% of previous rate. Use the 50% infusion rate for all subsequent administrations Prior G1/2 infusion-related reaction Premedicate with dexamethasone intravenously at commonly used antiemetic doses of 8–20 mg (or equivalent) and acetaminophen prior to each ramucirumab infusion. Continue diphenhydramine 25–50 mg intravenously G3/4 infusion-related reaction Permanently discontinue ramucirumab G3/4 hypertension Interrupt ramucirumab until symptoms controlled with medical management; if unable to control with medical management, discontinue ramucirumab PRES Permanently discontinue ramucirumab Urine protein ≥2 g/24 hours Interrupt ramucirumab. Reinitiate treatment at a reduced dose once the urine protein level returns to <2 g/24 hours Reoccurrence of urine protein ≥2 g/24 hours Interrupt ramucirumab and reduce the dose once the urine protein level returns to <2 g/24 hours Urine protein >3 g/24 hours or nephrotic syndrome Permanently discontinue ramucirumab Anticipated wound healing Stop ramucirumab ≥4 weeks prior to a scheduled surgery and until wound is fully healed; discontinue ramucirumab if patient develops wound healing complications G3/4 bleeding, arterial thromboembolic event, gastrointestinal perforation Permanently discontinue ramucirumab G3/4 Fatigue/asthenia Interrupt ramucirumab. Reinstitute treatment at a reduced dose once toxicity is G1 G3/4 Stomatitis/mucosal inflammation DOCETAXEL DOSE MODIFICATIONS Starting docetaxel dose 75 mg/m2 (recommended starting dose in East Asian patients = 60 mg/m2) Dose level −1* 65 mg/m2 Dose level −2* 50 mg/m2 Serum bilirubin > ULN Do not administer docetaxel AST and/or ALT >1.5× ULN with concomitant with alkaline phosphatase >2.5× ULN Do not administer docetaxel ANC <1500/mm3; platelet count <100,000/mm3 Withhold docetaxel until ANC >1500/mm3 and platelet count <100,000/mm3 ANC nadir <500 cells/mm3 for >1 week Reduce dose by 1 level in subsequent cycle Platelet nadir <25,000 cells/mm3 Febrile neutropenia Severe or cumulative cutaneous reactions from docetaxel Withhold treatment until toxicity improves, then resume with dose reduced by 1 level G3/4 nonhematologic toxicities Withhold treatment until toxicity improves to G1, then resume with dose reduced by 1 level Severe hypersensitivity reaction Immediately discontinue docetaxel infusion and administer dexamethasone intravenously at commonly used antiemetic doses 8–20 mg History of severe hypersensitivity to docetaxel or other drugs formulated with polysorbate 80 Do not administer docetaxel Minor flushing or localized skin reactions Interruption of therapy is not required ≥G3 peripheral neuropathy Discontinue docetaxel Fluid retention Treat with salt restriction and oral diuretics; reduce dose by 1 level Mild peripheral edema Treat with salt restriction and oral diuretics Abbreviations: ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate transaminase; PRES, Posterior reversible leukoencephalopathy syndrome; ULN, upper limit of normal *The U.S. FDA-approved package insert for docetaxel recommends only 1 dose reduction of docetaxel to 55 mg/m2 in patients with NSCLC after platinum failure; the dose levels listed above were included to allow for greater physician discretion. Notes: Patients who are pregnant or who becomes pregnant should be apprised of the potential hazard to the fetus. Females of childbearing potential should be advised to avoid becoming pregnant during therapy No dose adjustments for docetaxel or ramucirumab are recommended for patients with renal impairment Dose adjustments for hepatic impairment: Ramucirumab: No dose adjustment is recommended for patients with mild (total bilirubin within ULN and AST >ULN, or total bilirubin >1.0–1.5× ULN and any AST or moderate (total bilirubin >1.5-3.0× ULN and any AST) hepatic impairment Docetaxel: Use is not recommended for patients with total bilirubin > ULN, or AST and/or ALT >1.5× ULN concomitant with alkaline phosphatase >2.5× ULN + +Adverse Events (N = 1245) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Docetaxel + Ramucirumab Docetaxel + Placebo Grade (%)✫ Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Nonhematologic Adverse Events Fatigue 41 14 39 10 Diarrhea 27 5 25 3 Decreased appetite 27 2 24 1 Nausea 26 1 26 1 Alopecia 26 – 26 – Stomatitis 19 4 11 2 Neuropathy 20 3 19 2 Dyspnea 18 4 16 8 Cough 21 <1 20 1 Pyrexia 16 <1 13 <1 Peripheral edema 16 0 8 <1 Mucosal inflammation 13 3 6 <1 Constipation 16 <1 17 1 Vomiting 13 1 12 2 Lacrimation increased 13 <1 4 0 Myalgia 12 1 10 1 Arthralgia 10 1 7 1 Back pain 10 1 8 <1 Abdominal pain 10 1 9 1 Insomnia 10 <1 8 <1 Dysgeusia 11 – 7 – Headache 10 <1 10 1 Hypertension† 5 6 3 2 Infusion-related reaction† 3 1 4 1 Proteinuria† 3 <1 1 0 Renal failure† 2 <1 2 <1 Congestive heart failure† <1 1 <1 <1 Gastrointestinal perforation† <1 1 0 <1 Hematologic Adverse Events Neutropenia 6 49 6 39 Febrile neutropenia 0 16 0 10 Bleeding or hemorrhage† 26 2 13 2 Leucopenia 8 14 6 12 Anemia 18 3 22 6 Epistaxis† 18 <1 6 <1 Thrombocytopenia 11 3 5 1 Pulmonary hemorrhage† 7 1 6 1 Hemoptysis† 5 1 5 1 Gastrointestinal hemorrhage† 2 1 1 <1 Venous thromboembolic† <1 2 3 3 Arterial thromboembolic† <1 1 <1 1 ✫According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 † Denotes those events of special interest Notes: Toxicities are included in the table if all-grade events occurred in ≥10% of patients or were of special interest. Events are included regardless of whether they were caused by the study treatment.